Scisparc granted patent from the australian patent office for its reduction of opioids use in pain management technology

Tel aviv, israel, oct. 31, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been received notice of acceptance for its patent application for combination of opioids and n-acylethanolamines for pain treatment (the “patent”).
SPRC Ratings Summary
SPRC Quant Ranking